A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer (PEACE1)

• ClinicalTrials.gov Identifier: NCT01957436
• Recruitment Status: Active, not recruiting
• First Posted: October 8, 2013
• Last Update Posted: November 8, 2023
• Sponsor: UNICANCER
• Collaborators: Janssen-Cilag Ltd.; European Organisation for Research and Treatment of Cancer - EORTC; Ipsen; Sanofi
• Information provided by (Responsible Party): UNICANCER

Tracking Information

• First Submitted Date: September 24, 2013
• First Posted Date: October 8, 2013
• Last Update Posted Date: November 8, 2023
• Actual Study Start Date: November 13, 2013
• Actual Primary Completion Date: August 18, 2021 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 4, 2021)

• Survival [ Time Frame: 7.5 years after the first inclusion ]
  Overall and radiographic progression-free survival in patients with metastatic hormone-naïve prostate cancer treated by androgen deprivation therapy and docetaxel
• Survival [ Time Frame: 9.5 years after the first inclusion ]
  Overall and radiographic progression-free survival in hormone-naïve prostate cancer patients with low metastatic burden whatever the standard of care received

Original Primary Outcome Measures (submitted: September 30, 2013)

Survival [ Time Frame: 5.5 years after the first inclusion ]

Overall and progression-free survival

Current Secondary Outcome Measures (submitted: May 4, 2021)

• Castration resistance-free survival (CRFS) [ Time Frame: 9.5 years after the first inclusion ]
• Serious Genitourinary event-free survival (S-GU-EFS) [ Time Frame: 9.5 years after the first inclusion ]
• Prostate cancer specific survival [ Time Frame: 9.5 years after the first inclusion ]
• Time to next skeletal-related event [ Time Frame: 9.5 years after the first inclusion ]
• PSA response rate [ Time Frame: 9.5 years after the first inclusion ]
• Prospective correlative study of PSA response/progression at 8 months after initation of ADT [ Time Frame: 9.5 years after the first inclusion ]
• Time to pain progression [ Time Frame: 9.5 years after the first inclusion ]
  will be evaluated by questionnaires
• Time to chemotherapy for CRPC [ Time Frame: 9.5 years after the first inclusion ]
• Quality of life questionnaire - Core 30 (QLQ-C30) [ Time Frame: At baseline, 6 months, 18 months, and at the end of treatment (up to 9.5 years) ]
  Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.
• Functional Assessment of Cancer Therapy - Prostate (FACT-P) [ Time Frame: At baseline, 6 months, 12 months, 18 months, and at the end of treatment (up to 9.5 years) ]
  The FACT-P is a self-assessment questionnaire to estimate the health-related quality of life in men with prostate cancer. This questionnaire, composed of 39 items consists of four subscales: Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), Functional Well-Being (7 items), and prostate cancer subscale (12 items). Subscales are rated on 5-point Likert-type scale (from 0 = "Not at all" to 4 = "Very much"). For all subscales, a higher score represents better quality of life.
• Toxicity (with a specific focus on the use of long-term low-dose steroids) [ Time Frame: Throughout study completion, up to 9.5 years ]
  The National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.
• Changes in bone mineral density [ Time Frame: At baseline, 6 months, 12 months, and 24 months ]
  X-rays are used to measure how many grams of calcium and other bone minerals are packed into a segment of bone
• Correlation of biomarkers with outcome [ Time Frame: 9.5 years after the first inclusion ]
  Correlation of biomarkers with outcome, including the prognostic and predictive value on OS, rPFS and CRFS of a neuro-endocrine differentiation of the prostate cancer in the pathological specimen.

Original Secondary Outcome Measures (submitted: September 30, 2013)

• PSA response rate [ Time Frame: 8 months ]
  The PSA response rate will be defined by an undetectable serum PSA level at 8 months
• Prospective correlative study of PSA response/progression [ Time Frame: 8 months ]
• Prostate cancer specific survival [ Time Frame: 5.5 years ]
• Time to pain progression [ Time Frame: 5.5 years ]
  will be evaluated by questionnaires
• Time to next skeletal-related event [ Time Frame: 5.5 years ]
• Time to chemotherapy [ Time Frame: 5.5 years ]
• Time to severe local symptoms [ Time Frame: 5.5 years ]
  The time to severe local symptoms (grade 3 and 4 events) related to tumor progression and/or radiotherapy long term side effets will be evaluated according to NCI-CTCAE v4.0
• Toxicity [ Time Frame: 5.5 years ]
  Toxicity (with a specific focus on the use of long-term low-dose steroids) will be evaluated according to NCI-CTCAE v4.0
• The radiological progression-free survival [ Time Frame: 5.5 years ]
• Impact of radiotherapy protocol on outcome [ Time Frame: 5.5 years ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
• Official Title: A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
• Brief Summary: This is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.

Detailed Description

Eligible patients can be randomize in the trial after his consent form has been signed, and after all inclusion and non-inclusion criteria have been checked.

The randomisation will result in the allocation of arm A (ADT +docetaxel), arm B (ADT +docetaxel +Abiraterone), arm C (ADT +docetaxel +radiotherapy) or arm D (ADT +docetaxel +Abiraterone +radiotherapy) in a 1:1:1:1 ratio.

The randomization will be stratified (by minimization) according to:

• enrolment center,
• performance status (0 vs. 1-2)
• disease extent: lymph nodes only vs. bone (with or without lymph nodes) vs. presence of visceral metastases.

CRPC is defined by cancer progression (either a confirmed PSA rise or a radiological progression) with serum testosterone being at castrated levels (<0.50 ng/mL).

When the CRPC stage is reached, castration (either LHRH agonist or LHRH antagonist) will be maintained in all patients.

Investigators will be free to manage patients reaching CRPC at their discretion (using for example docetaxel, zoledronic acid, denosumab, sipuleucel-T, radium-223, cabazitaxel, etc) according to local uses and guidelines.

Abiraterone may be used in arm A and C if abiraterone has become the standard treatment for CRPC when this stage is reached.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Metastatic Prostate Cancer

Intervention

• Drug: abiraterone acetate
  abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
  Other Name: Zytiga
• Radiation: radiotherapy
  74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
• Other: Androgen Deprivation Therapy
  The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
• Drug: Docetaxel
  6 cycles at 75mg/m²/cycle, one cycle every 3 weeks

Study Arms

• Active Comparator: Arm A
  androgen deprivation therapy + docetaxel
  Interventions:

  • Other: Androgen Deprivation Therapy
  • Drug: Docetaxel
• Experimental: Arm B
  androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
  Interventions:

  • Drug: abiraterone acetate
  • Other: Androgen Deprivation Therapy
  • Drug: Docetaxel
• Experimental: Arm C
  Arm A + radiotherapy
  Interventions:

  • Radiation: radiotherapy
  • Other: Androgen Deprivation Therapy
  • Drug: Docetaxel
• Experimental: Arm D
  Arm B + radiotherapy
  Interventions:

  • Drug: abiraterone acetate
  • Radiation: radiotherapy
  • Other: Androgen Deprivation Therapy
  • Drug: Docetaxel

• Publications *: Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: January 24, 2019): 1173
• Original Estimated Enrollment (submitted: September 30, 2013): 916
• Estimated Study Completion Date: December 2032
• Actual Primary Completion Date: August 18, 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion criteria:

1. Histologically or cytologically confirmed adenocarcinoma of the prostate,

2. Metastatic disease documented by a positive bone scan (any technique) or CT scan or an MRI. For patients with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes (lymph nodes located above the iliac bifurcation) can be included if they have either:

   o At least one extra-pelvic lymph node ≥ 2 cm or extra-pelvic lymph node (s) ≥ 1 cm if the patients also have at least one pelvic lymph node ≥ 2 cm

3. Patients with ECOG ≤ 1 (patient with PS 2 due to bone pain can be accrued in the trial),
4. Life expectancy of at least 6 months,
5. Male aged ≥ 18 years old and ≤ 80 years old ,

6. Hematology values:

   • Hemoglobin ≥ 10.0 g/dL,
   • Platelet count ≥ 100,000/mL,
   • Neutrophil ≥ 1500 cells/mm³

7. Biochemistry values:

   • Renal function: Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min,
   • Serum potassium ≥ 4 mmol/L,

   • Liver function:

     • Serum bilirubin ≤ 1.5 x ULN (except for patients with documented Gilbert's disease),
     • AST and ALT ≤ 1.5 x ULN (and ≤ 5 ULN in case of liver metastases),
   • ALK-P ≤ 2.5 x ULN (in case of bone metastasis, ALK-P<1000U/L if bilirubin is normal)
8. Patients must have received ADT for a maximum of 3 months before randomization and there must be a minimum of 6 weeks between the start of ADT and the start of Docetaxel,

9. Patients willing and clinically fit to receive Docetaxel which is defined by the following :

   • Patients respecting all inclusion and exclusion criteria And
   • Patients with no contraindication to docetaxel according to the SmPC of the drug And
   • Patients presenting all medical requirements to receive docetaxel according to the investigator's opinion.
10. Patients might have received previous radiation therapy directed to bone lesions,
11. Patients able to take oral medication,
12. Patients who have received the information sheet and signed the informed consent form,
13. Male patients who will receive Docetaxel and/or Abiraterone acetate and have partners of childbearing potential and/or pregnant partners must use a method of birth control in addition to an adequate barrier protection (condoms) as determined to be acceptable by the study doctor during the treatment period and for 4 weeks after the last dose of abiraterone acetate and/or for 6 months after the last dose of Docetaxel
14. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,
15. Patients with a public or a private health insurance coverage, according to local laws for participation in clinical trials.

Exclusion Criteria:

1. Patients with previous definitive local treatment directed to the prostate primary cancer (radiotherapy, brachytherapy, radical prostatectomy, ultrasound, cryotherapy, or other). A previous trans-urethral resection of the prostate (TURP) and previous local treatments of metastases are allowed,
2. Prior cytotoxic chemotherapy or biological therapy for the treatment of prostate cancer,
3. Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg prednisone/prednisolone twice daily,
4. Active infection or other medical condition for which prednisone/prednisolone (corticosteroid) use would be contra-indicated,
5. Previously treated with ketoconazole for prostate cancer for more than 7 days,
6. Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of randomization,
7. Hypertension not controlled by an anti-hypertensive treatment (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg; 3 consecutive measures taken 5 minutes apart),
8. Severe or moderate hepatic impairment (Child - Pugh class C or B)
9. Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert's disease),
10. History of pituitary or adrenal dysfunction,
11. Clinically known significant heart disease in the past 6 months as evidenced by myocardial infarction, or arterial thrombotic events, severe or unstable angina, or New York Heart association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 50% at baseline,
12. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy,
13. Patient with unstable pulmonary disease (eg. Pulmonary embolism)
14. Pathological finding consistent with small cell carcinoma of the prostate,
15. History of malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of recurrence within 24 months,
16. Known allergies, hypersensitivity or intolerance to the study drugs or excipients or docetaxel
17. Administration of an investigational therapeutic within 30 days of randomization,
18. Patients already included in another therapeutic trial involving an experimental drug (patient in a non-experimental trial with no modification of the patient's care can be included),
19. Patients with significantly altered mental status prohibiting the understanding of the study or with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule or any condition which, in the opinion of the investigator, would preclude participation in this trial. Those conditions should be discussed with the patient before registration in the trial,
20. Individual deprived of liberty or placed under the authority of a tutor.

21. Patients with impaired vision should undergo a prompt and complete ophthalmologic examination.

    Patients with Cystoid Macular Oedema cannot be included due to a potential risk of deterioration associated with docetaxel.

22. Concomitant use of strong CYP3A4 inhibitors (clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin.)

Sex/Gender

• Sexes Eligible for Study: Male

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Belgium, France, Ireland, Italy, Romania, Spain, Switzerland
• Removed Location Countries: Germany, Portugal

Administrative Information

• NCT Number: NCT01957436
• Other Study ID Numbers: UC-0160/1105 GETUG AFU-21
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No
• Plan Description: Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

• Current Responsible Party: UNICANCER
• Original Responsible Party: Same as current
• Current Study Sponsor: UNICANCER
• Original Study Sponsor: Same as current

Collaborators

• Janssen-Cilag Ltd.
• European Organisation for Research and Treatment of Cancer - EORTC
• Ipsen
• Sanofi

Investigators

• Study Chair: Karim FIZAZI, Professor; Gustave Roussy, Cancer Campus Grand Paris - Paris
• Study Chair: Alberto BOSSI, Doctor; Gustave Roussy, Cancer Campus Grand Paris - Paris

• PRS Account: UNICANCER
• Verification Date: November 2023